28.25
1.53%
+0.45
10x Genomics Inc stock is currently priced at $28.25, with a 24-hour trading volume of 1.11M.
It has seen a +1.53% increased in the last 24 hours and a -22.22% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $27.85 pivot point. If it approaches the $28.30 resistance level, significant changes may occur.
10x Genomics Inc Stock (TXG) Financials Data
10x Genomics Inc (TXG) Revenue 2024
TXG reported a revenue (TTM) of $618.73 million for the quarter ending December 31, 2023, a +19.81% rise year-over-year.
10x Genomics Inc (TXG) Net Income 2024
TXG net income (TTM) was -$255.10 million for the quarter ending December 31, 2023, a -53.67% decrease year-over-year.
10x Genomics Inc (TXG) Cash Flow 2024
TXG recorded a free cash flow (TTM) of -$64.72 million for the quarter ending December 31, 2023, a +60.84% increase year-over-year.
10x Genomics Inc (TXG) Earnings per Share 2024
TXG earnings per share (TTM) was -$2.17 for the quarter ending December 31, 2023, a -47.62% decline year-over-year.
10x Genomics Inc Stock (TXG) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Saxonov Serge | Chief Executive Officer |
Feb 22 '24 |
Sale |
46.34 |
2,821 |
130,737 |
847,560 |
Hindson Benjamin J. | See Remarks |
Feb 22 '24 |
Sale |
46.34 |
2,613 |
121,098 |
283,059 |
McAnear Justin J. | Chief Financial Officer |
Feb 22 '24 |
Sale |
46.34 |
1,865 |
86,432 |
95,240 |
Saxonov Serge | Chief Executive Officer |
Feb 15 '24 |
Sale |
48.87 |
5,000 |
244,332 |
850,381 |
Saxonov Serge | Chief Executive Officer |
Feb 09 '24 |
Sale |
49.53 |
1,000 |
49,530 |
855,381 |
Saxonov Serge | Chief Executive Officer |
Jan 16 '24 |
Sale |
45.24 |
4,000 |
180,956 |
856,381 |
Hindson Benjamin J. | See Remarks |
Dec 28 '23 |
Option Exercise |
11.48 |
8,334 |
95,674 |
285,672 |
Saxonov Serge | Chief Executive Officer |
Dec 27 '23 |
Option Exercise |
1.20 |
14,935 |
17,922 |
860,381 |
Saxonov Serge | Chief Executive Officer |
Dec 14 '23 |
Sale |
55.03 |
2,000 |
110,065 |
845,446 |
Saxonov Serge | Chief Executive Officer |
Nov 24 '23 |
Sale |
43.72 |
3,723 |
162,751 |
847,446 |
10x Genomics Inc Stock (TXG) Latest News
10x Genomics (TXG) Expected to Beat Earnings Estimates: Should You Buy?
Zacks Investment Research
Geopolitical Relief Triggers Gold Selloff: Prices Dip Below $2,350 Mark, Mining Stocks Hit Hard
Benzinga
10x Genomics (TXG) Upgraded to Buy: Here's What You Should Know
Zacks Investment Research
Tracking Cathie Wood's ARK Invest 13F Portfolio - Q1 2024 Update
Seeking Alpha
The Analyst Landscape: 4 Takes On 10x Genomics
Benzinga
Cathie Wood's Ark Invest Sheds $6.4M Worth Of Coinbase Shares Despite Positive Market Movements, Analyst Upgrade
Benzinga
About 10x Genomics Inc
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. Its company offers chromium instruments, enzymes, microfluidic chips, slides, reagents, and other consumable products. The company's single cell solution runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics, including the physical organization of DNA; single cell CNV for measuring cellular heterogeneity through DNA changes, such as copy number variation; and visium spatial gene expression solution that measures the spatial gene expression patterns across a tissue sample. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10X Genomics, Inc. in November 2014. 10x Genomics, Inc. was founded in 2012 and is headquartered in Pleasanton, California.
Cap:
|
Volume (24h):